P=N/A, N=1000, Not yet recruiting, Xiangya Hospital of Central South University

A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.

Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.

P=N/A, N=155, Active, not recruiting, Alfasigma S.p.A. | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026

P2, N=57, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting

P3, N=80, Recruiting, Alfasigma S.p.A. | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Jun 2028

P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2029 --> Jan 2030 | Trial primary completion date: Oct 2027 --> Jan 2028

P=N/A, N=183, Recruiting, Pfizer | Trial completion date: May 2027 --> Dec 2027

P=N/A, N=60, Recruiting, Xijing Hospital

This WES-AI-ML framework provides mutation-guided therapies for BC-CML, enabling real-time stratification and Food and Drug Administration-approved drug repurposing. While this exploratory study is limited by its small sample size (n = 7), it establishes a methodological framework for precision oncology stratification that warrants validation in larger, multi-center cohorts.

P2, N=120, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P1, N=20, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID)